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with either segmental (‘IV-S’) or global (‘IV-G’) distribution
of lesions as published data so far has failed to show a worse
outcome between these groups. They also quote one
publication in which the authors conclude that this
subclassification ‘may not be justified.’3
Poorer renal prognosis in pediatric LN may be due to
different etiopathogenesis. We found a worse outcome in
children with class IV-G LN in our published data of 39 cases
(85% female) aged 3.3–18.0 (median 13.7) years at our single
center over 10 years.4 Patients underwent 49 percutaneous
renal biopsies at 0.1–7.8 (median 1.0) years from diagnosis of
systemic lupus erythematosus with renal and overall survival
rates of 90 and 92% respectively at a follow-up of 1.3–15.4
(median 5.5) years. In our cohort, the three most severe cases
of chronic kidney disease with estimated glomerular filtration
rate o25 ml/min/1.73 m2 were patients with diffuse global
sclerosing (class IV-G(C)) LN. Therefore, we require larger
studies of pediatric LN to evaluate progression of disease and
guide physicians on treatment.
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To the Editor: In a paper published in Kidney International,
Coto et al.1,2 described a SLC12A3 mutation, IVS9þ 1G4T,
subsequently shown to result in aberrant splicing and exon
skipping. The 21 homozygote patients known so far belong
to unrelated Gypsy families from Spain, Portugal, France, and
Germany, suggesting that IVS9þ 1G4T is a shared ancestral
mutation.1,2 To provide more comprehensive data on its
molecular epidemiology in European Gypsies, we tested a
panel of 599 unrelated control subjects of Roma/Gypsy
ethnicity from Bulgaria (representing eight different sub-
isolates), Romania, Hungary, the Czech Republic, and Spain.
Amplification refractory mutation system-polymerase chain
reaction was used for screening (conditions available upon
request), with positive results verified by restriction-fragment
length polymorphism.1 We detected 12 heterozygotes,
randomly spread between sub-isolates and geographic
locations, pointing to a founder effect common to the entire
European Gypsy population. The overall carrier rate is 2%,
ranging between 0 and 7% in different sub-isolates. Given the
variable and often nonspecific clinical manifestations of
Gitelman syndrome,3 this information should facilitate the
diagnosis and management of affected Gypsy individuals.
The allelic heterogeneity of Gitelman syndrome, with over
100 mutations in SLC12A3 identified to date, has made
genotype–phenotype correlations problematic.3 The observed
clinical heterogeneity in individuals homozygous for the
same mutation points to the potential role of modifying
genes.1,4 The IVS9þ 1G4T founder mutation, with an
expected incidence of affected homozygotes of 1:10 000
across Europe (up to 1:800 in some sub-isolates), should
allow the collection of large numbers of genetically homo-
geneous patients, where phenotype diversity can be char-
acterized further and the search for modifying factors can
begin.
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